whats better semaglutide or tirzepatide vs Tirzepatide: Which Is Right for You? Tirzepatide vs Semaglutide Compared |

nausea common but usually mild Weeks 5-12 (0.5 to 1.0 mg doses): Accelerated weight loss, 0.5-1% of body weight per week Appetite suppression becomes pronounced This is the phase where patients report "forgetting to eat" or feeling full after small portions Cumulative weight loss by week 12: 5-8% of baseline body weight Weeks 13-28 (1.7 to 2.4 mg doses): Continued weight loss at 0.3-0.5% per week Rate of loss slows compared to weeks 5-12, but total loss continues to accumulate Cumulative weight loss by week 28: 10-13% of baseline body weight Weeks 29-68 (2.4 mg maintenance): Weight loss continues but at a slower rate, approximately 0.1-0.2% per week Most patients plateau between weeks 60 and 68 Final cumulative weight loss: 14-17% of baseline body weight in trial populations, 12-15% in real-world populations Beyond 68 weeks: Weight typically stabilizes if treatment continues STEP 5 data shows no further significant loss after week 68, but also no regain if medication continues Discontinuation results in gradual weight regain, with most patients returning to 50-70% of their original weight within 12 months (STEP 4 data) Individual variation is substantial

Improper dosing from pen splitting can intensify side effects like nausea and vomiting, and has contributed to a significant rise in poison control calls

Note that routine amylase/lipase monitoring is not recommended in asymptomatic patients

Note: ShedRx offers the most diverse medication format menu in this review series, four semaglutide delivery formats (injectable, drops, lozenges, liposomal tablets) and two tirzepatide formats, plus brand-name Wegovy and Zepbound

HOMA-IR (Calculated) What it measures: A calculated estimate of insulin resistance using fasting glucose and fasting insulin: (Glucose x Insulin) / 405

[DOI] [PMC free article] [PubMed] [Google Scholar] 112.Napolitano A., Miller S., Nicholls A.W., Baker D., Van Horn S., Thomas E., Rajpal D., Spivak A., Brown J.R., Nunez D.J